Skip to main content
MedPathMedPath Home
Clinical Trials/ISRCTN81349394
ISRCTN81349394
Completed
未知

The Effect of Intraoperative N-Acetylcysteine on Hepatocellular Injury During Laparoscopic Bariatric Surgery: A Randomised Controlled Trial

King's College Hospital NHS Foundation Trust (UK)0 sites80 target enrollmentFebruary 28, 2008
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMorbid obesity /non-alcoholic fatty liver diseaseNutritional, Metabolic, Endocrine

Overview

Phase
未知
Intervention
Not specified
Conditions
Morbid obesity /non-alcoholic fatty liver disease
Sponsor
King's College Hospital NHS Foundation Trust (UK)
Enrollment
80
Status
Completed
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 28, 2008
End Date
TBD
Last Updated
9 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
King's College Hospital NHS Foundation Trust (UK)

Eligibility Criteria

Inclusion Criteria

  • •1\. Male or Female
  • •2\. Aged 18 to 65
  • •3\. National Institute of Clinical Excellence criteria for morbid obesity surgery: BMI \>40 or BMI \>35 with obesity related complications

Exclusion Criteria

  • •1\. Pregnancy
  • •2\. History of chronic liver disease, including viral hepatitis, haemachromatosis, alcoholic liver disease or known alcohol intake \>20g/day
  • •3\. Previous liver surgery, e.g., resection, orthotopic transplantation
  • •4\. Psychiatric illness, including anxiety, mood and eating disorders
  • •5\. Bleeding tendency or anticoagulant medications
  • •6\. Known allergies to N\-acetylcysteine or related compounds

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
The effect of intraoperative N-acetylcysteine on hepatocellular injury during laparoscopic bariatric surgery. A randomised controlled trial. - Randomised trial of N-acetylcysteine in laparoscopic bariatric surgeryon-Alcoholic Fatty Liver Disease in patients undergoing weight-loss (bariatric) surgeryMedDRA version: 9.1Level: LLTClassification code 10031743Term: Other chronic nonalcoholic liver disease
EUCTR2008-001677-15-GBKing's College Hospital NHS Foundation Trust80
Not yet recruiting
Phase 2
protective effect of N-acetylcysteine on taxane neuropathyPeripheral neuropathy.Polyneuropathy in diseases classified elsewhere
IRCT20090613002027N20Mazandaran University of Medical Sciences60
Completed
Phase 3
Evaluation of The Effect of N-acetylcysteine in The Prevention of Vancomycin-Induced Renal Disorder
IRCT20150721023282N3Esfahan University of Medical Sciences80
Completed
Phase 3
Effects of N-acetylcysteine administration in treatment of women with gestational diabetes mellitusGestational diabetes mellitus.Unspecified diabetes mellitus in pregnancy, childbirth and the puerperiumO24.9
IRCT20170513033941N71Kashan University of Medical Sciences76
Recruiting
Phase 3
Preoperative intranenous N-Acetylcysteine for the prevention of renal failure in patients with renal impairment undergoing cardiac surgeryRenal Impairment in cardiac surgeryRenal and Urogenital - Other renal and urogenital disordersCardiovascular - Other surgery
ACTRN12606000088549Prince of Wales Hospital200